Skip to content
Screener

Indivior Pharmaceuticals, Inc. INDV Total Revenue

Total Revenue at other companies

Collegium Pharmaceutical, Inc. logo
Collegium Pharmaceutical, Inc.COLL
$199.88M+6.3%
Aquestive Therapeutics, Inc. logo
Aquestive Therapeutics, Inc.AQST
$14.45M+65.7%
Alkermes logo
AlkermesALKS
$496.01M+27.0%
Emergent Biosolutions logo
Emergent BiosolutionsEBS
$234.3M+66.3%

Segments

By product

See full
SUBLOCADE$232M+31.8%
Sublingual & other$50M-7.4%
PERSERIS$5M+25.0%

By segment

See full
Reportable Segment$317M+19.2%

By geography

See full
Rest of World$45M+2.3%

Other financials

Income statement

See full
Gross profit$277.0M+24.8%
Operating income$137.0M+108%
Net income$89.0M+89.4%
EPS (diluted)$0.69+81.6%

Balance sheet

See full
Cash & equivalents$175.0M-53.0%
Total debt$509.0M+37.6%
Total equity-$144.0M+49.5%
Total assets$1.2B-12.9%

Cash flow

See full
Operating cash flow-$9.0M-112%
CapEx$20.0M+300%
Free cash flow-$29.0M-141%

Valuation

See full
Market cap$4.57B+66.5%
Enterprise value$4.9B+88.6%
P/E18.2×-7.2×
P/S3.5×+1.2×

Profitability

See full
Gross margin81.3%+1.5pp
Operating margin25.8%+23.3pp
Net margin19.4%+18.9pp
FCF margin-14.9%—

Returns & leverage

See full
Return on equity-117%—
Debt / equity-3.5×—
Current ratio0.9×0.0×

Where this comes from

Reported directly by Indivior Pharmaceuticals, Inc. in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The source filing: Indivior Pharmaceuticals, Inc.’s 10-Q, filed April 30, 2026.

Filed
Apr 30, 2026, 4:02 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001628280-26-028850
Line itemThree Months Ended March 31, 20262025
Net revenue$317$266
Cost of sales4044
Gross profit277221
Operating expenses:
Selling, general and administrative124133
Research and development1622
Total operating expenses139156
Operating income13766

Item 1. Unaudited Condensed Financial Statements.

FAQ

What is Indivior Pharmaceuticals, Inc.'s total revenue?
Indivior Pharmaceuticals, Inc. (INDV) reported total revenue of $317M in Q1 2026.
How has Indivior Pharmaceuticals, Inc.'s total revenue changed year-over-year?
Indivior Pharmaceuticals, Inc.'s total revenue increased by 19.2% year-over-year, from $266M to $317M.
What is the long-term trend for Indivior Pharmaceuticals, Inc.'s total revenue?
Over 3 years (2022 to 2025), Indivior Pharmaceuticals, Inc.'s total revenue has grown at a 11.2% compound annual growth rate (CAGR), from $901M to $1.24B.
What does total revenue mean?
The aggregate of all revenue from the company's operations — the top line from which all profitability metrics are derived.

Ask your AI about Indivior Pharmaceuticals, Inc.'s total revenue.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude